Welch & Forbes LLC Sells 669 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Welch & Forbes LLC cut its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 6.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,022 shares of the company’s stock after selling 669 shares during the quarter. Welch & Forbes LLC’s holdings in GE HealthCare Technologies were worth $705,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. LGT Financial Advisors LLC increased its stake in shares of GE HealthCare Technologies by 1,673.3% in the 3rd quarter. LGT Financial Advisors LLC now owns 266 shares of the company’s stock worth $25,000 after acquiring an additional 251 shares in the last quarter. Capital Performance Advisors LLP bought a new position in shares of GE HealthCare Technologies in the 3rd quarter worth about $26,000. Ashton Thomas Securities LLC bought a new position in shares of GE HealthCare Technologies in the 3rd quarter worth about $26,000. Darwin Wealth Management LLC bought a new position in shares of GE HealthCare Technologies in the 3rd quarter worth about $31,000. Finally, Continuum Advisory LLC increased its stake in shares of GE HealthCare Technologies by 101.8% in the 3rd quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after acquiring an additional 168 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

GEHC has been the subject of a number of analyst reports. Citigroup raised their price objective on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Jefferies Financial Group upgraded shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and raised their price objective for the company from $95.00 to $103.00 in a research note on Wednesday, January 8th. Finally, Wells Fargo & Company raised their price objective on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $97.67.

GE HealthCare Technologies Trading Up 1.4 %

GE HealthCare Technologies stock opened at $86.58 on Friday. The stock has a market cap of $39.59 billion, a P/E ratio of 20.00, a PEG ratio of 3.19 and a beta of 1.13. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 0.83. GE HealthCare Technologies Inc. has a 1 year low of $74.51 and a 1 year high of $94.80. The firm’s 50 day moving average price is $86.63 and its 200-day moving average price is $86.13.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.19. The firm had revenue of $5.32 billion for the quarter, compared to analysts’ expectations of $5.33 billion. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. On average, equities analysts predict that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current fiscal year.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.